Clinical Trial Update: Exploratory Study of Danicamtiv in Patients With Primary Dilated Cardiomyopathy (DCM) Due to Genetic Variants or Other Causalities [Phase 2]

View source ↗

Summary

A Phase 2 exploratory trial of Danicamtiv in primary dilated cardiomyopathy, including familial/genetic cases, was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dilated Cardiomyopathy
• Familial Dilated Cardiomyopathy

Drugs mentioned

• Danicamtiv (Danicamtiv)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Primary Familial Dilated Cardiomyopathy | Phase 2 | Status: TERMINATED | Results posted: 2025-05-21